FEATURES

Viewpoints

Topical Gel May Be as Effective as Oral Tamoxifen in DCIS

Topical Gel May Be as Effective as Oral Tamoxifen in DCIS

A topical gel containing an active metabolite of tamoxifen suppressed cell proliferation equally as well as the oral form.

Supreme Court Ruling Puts Gynecologic Cancer Prevention at Risk

Supreme Court Ruling Puts Gynecologic Cancer Prevention at Risk

SCOTUS decision in Hobby Lobby case reaches beyond contraception.

Feature Articles

Oncologists Asked to Play Greater Role in Helping Obese Patients With Cancer

Oncologists Asked to Play Greater Role in Helping Obese Patients With Cancer

ASCO recommendation tasks oncologists with assisting obese patients with cancer in finding appropriate resources for weight management.

Helping Patients With Cancer Avoid Financial Toxicity

Helping Patients With Cancer Avoid Financial Toxicity

Cancer care costs are becoming a significant problem; however, a new tool may help oncologists assess how patients will be affected by treatment expenses.

'Truly Personalized Medicine' Emphasizes Value—Not Cost—of Cancer Care

'Truly Personalized Medicine' Emphasizes Value—Not Cost—of Cancer Care

With the cost of cancer care rising, an ASCO task force has been established to create a framework for assessing relative value of cancer treatment.

Slideshows

SYLATRON® (peginterferon alfa-2b)

SYLATRON® (peginterferon alfa-2b)

Review slide-by-slide drug information for SYLATRON® (peginterferon alfa-2b) for treatment of melanoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 8: ...

XELODA®

XELODA®

This slideshow reviews drug information for XELODA® (capecitabine) for treatment of metastatic breast cancer.

Table of Contents

Slide 3: Indication, Dosage, and ...

From the Advisory Board

The Promise of PD-1/PD-L1 Antagonists in Treating Metastatic Melanoma

The Promise of PD-1/PD-L1 Antagonists in Treating Metastatic Melanoma

Mario Sznol, MD, comments on the results of his phase 1 study reporting on data from patients with metastatic melanoma treated with nivolumab.

CME

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.

CTA Community Poll

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs